We are live on ! Find out more
ONCY

Oncolytics Biotech
ONCY

45 hedge funds and large institutions have $1.69M invested in Oncolytics Biotech in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 4 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

22% more funds holding

Funds holding: 37 → 45 (+8)

0.28% more ownership

Funds ownership: 1.91% → 2.2% (+0.28%)

39% less capital invested

Capital invested by funds: $2.79M → $1.69M (-$1.1M)

Holders
45
Holders Change
+8
Holders Change %
+21.62%
% of All Funds
0.69%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
11
Reduced
4
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ARC
Advisor Resource Council
Texas
+$185K
2
Citadel Advisors
Citadel Advisors
Florida
+$145K
3
TSS
Two Sigma Securities
New York
+$50.1K
4
Renaissance Technologies
Renaissance Technologies
New York
+$47.3K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$36.9K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$206K
2
UBS Group
UBS Group
Switzerland
-$43.4K
3
Bank of America
Bank of America
North Carolina
-$22.5K
4
CCM
Chiron Capital Management
Florida
-$21K
5
CGA
Crescent Grove Advisors
Illinois
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$327K +$47.3K +25,578 +12%
IAIM
2
International Assets Investment Management
Florida
$241K +$5.43K +2,935 +2%
ARC
3
Advisor Resource Council
Texas
$139K +$185K +100,000 New
Citadel Advisors
4
Citadel Advisors
Florida
$133K +$145K +78,347 +461%
Morgan Stanley
5
Morgan Stanley
New York
$122K +$8.13K +4,398 +5%
CIBC World Market
6
CIBC World Market
Ontario, Canada
$84K -$1.9K -1,025 -2%
Two Sigma Advisers
7
Two Sigma Advisers
New York
$59K +$5.55K +3,000 +8%
Royal Bank of Canada
8
Royal Bank of Canada
Ontario, Canada
$58K +$1.7K +921 +2%
LFCM
9
Long Focus Capital Management
Puerto Rico
$56K +$73.9K +40,000 New
JP Morgan Chase
10
JP Morgan Chase
New York
$50K -$206K -111,238 -75%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$48K – – –
Dimensional Fund Advisors
12
Dimensional Fund Advisors
Texas
$47K – – –
Bank of Montreal
13
Bank of Montreal
Ontario, Canada
$43K +$36.9K +19,982 +190%
TSS
14
Two Sigma Securities
New York
$38K +$50.1K +27,125 New
Comerica Bank
15
Comerica Bank
Texas
$31K – – –
LPL Financial
16
LPL Financial
California
$29K +$43 +23 +0.1%
BAM
17
Brave Asset Management
New Jersey
$28K – – –
Bank of America
18
Bank of America
North Carolina
$21K -$22.5K -12,160 -45%
NDSI
19
Newman Dignan & Sheerar Inc
Rhode Island
$19K +$1.85K +1,000 +8%
BCV
20
Banque Cantonale Vaudoise
Switzerland
$16K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$14K +$18.6K +10,059 New
NFG
22
Next Financial Group
Texas
$12K – – –
CMA
23
Cedar Mountain Advisors
Oregon
$8K – – –
DI
24
Disciplined Investments
Oklahoma
$7K – – –
Rockefeller Capital Management
25
Rockefeller Capital Management
New York
$7K – – –
1
2

ONCY Hedge Fund Activity: Q4 2021 in Review

45 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q4 2021, worth a combined $1.69M — down 39% from $2.79M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ONCY positions and 4 closed out — a net gain of 8 holders — while 11 added to existing stakes and 4 trimmed.

The largest buyer was Advisor Resource Council, opening a new position worth an estimated $185K. The largest seller was JP Morgan Chase, cutting an estimated $206K.

  • 45 institutional investors held Oncolytics Biotech (ONCY) as of Q4 2021, up from 37 in Q3 2021.
  • Funds reported $1.69M of Oncolytics Biotech stock for Q4 2021, down 39% quarter-over-quarter.
  • 12 funds opened new Oncolytics Biotech positions in Q4 2021 and 4 closed out, a net change of +8 holders.
  • The largest Oncolytics Biotech buyer in Q4 2021 was Advisor Resource Council, an estimated $185K added.
  • The largest Oncolytics Biotech seller in Q4 2021 was JP Morgan Chase, an estimated $206K sold.

Based on aggregated 13F filings for Q4 2021.